Improved Genotyping of N-acetyltransferase 2: Role of the Ultra-slow Acetylators

Overview

Journal EXCLI J

Specialty Biology

Date 2016 Apr 2

PMID 27034641

Citations 1

Authors

Meinolf Blaszkewicz

Affiliations

Soon will be listed here.

Citing Articles

Impact of urinary bladder cancer risk variants on prognosis and survival.

Selinski S EXCLI J. 2015; 13:1254-8.

PMID: 26417338 PMC: 4462828.

References

Hung R, Boffetta P, Brennan P, Malaveille C, Hautefeuille A, Donato F . GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int J Cancer. 2004; 110(4):598-604. DOI: 10.1002/ijc.20157. View

Hein D . Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res. 2002; 506-507:65-77. DOI: 10.1016/s0027-5107(02)00153-7. View

Golka K, Selinski S, Lehmann M, Blaszkewicz M, Marchan R, Ickstadt K . Genetic variants in urinary bladder cancer: collective power of the "wimp SNPs". Arch Toxicol. 2011; 85(6):539-54. DOI: 10.1007/s00204-011-0676-3. View

Partosch F, Mielke H, Gundert-Remy U . Functional UDP-glucuronyltransferase 2B15 polymorphism and bisphenol A concentrations in blood: results from physiologically based kinetic modelling. Arch Toxicol. 2013; 87(7):1257-64. DOI: 10.1007/s00204-013-1022-8. View

Bing C, Xiaomeia C, Jinhenga L . Gene dose effect of NAT2 variants on the pharmacokinetics of isoniazid and acetylisoniazid in healthy Chinese subjects. Drug Metabol Drug Interact. 2011; 26(3):113-8. DOI: 10.1515/DMDI.2011.016. View

Costa G, Magno L, Santana C, Konstantinovas C, Saito S, Machado M . Genetic interaction between NAT2, GSTM1, GSTT1, CYP2E1, and environmental factors is associated with adverse reactions to anti-tuberculosis drugs. Mol Diagn Ther. 2012; 16(4):241-50. DOI: 10.1007/BF03262213. View

Golka K, Prior V, Blaszkewicz M, Bolt H . The enhanced bladder cancer susceptibility of NAT2 slow acetylators towards aromatic amines: a review considering ethnic differences. Toxicol Lett. 2002; 128(1-3):229-41. DOI: 10.1016/s0378-4274(01)00544-6. View

Luck H, Kinzig M, Jetter A, Fuhr U, Sorgel F . Mesalazine pharmacokinetics and NAT2 phenotype. Eur J Clin Pharmacol. 2008; 65(1):47-54. DOI: 10.1007/s00228-008-0550-2. View

Daly A . Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms. Arch Toxicol. 2013; 87(3):407-20. DOI: 10.1007/s00204-013-1013-9. View

10.

An H, Wu X, Wang Z, Zhang J, Liang Y . NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients. Clin Exp Pharmacol Physiol. 2012; 39(6):535-43. DOI: 10.1111/j.1440-1681.2012.05713.x. View

11.

Golka K, Prior V, Blaszkewicz M, Cascorbi I, Schops W, Kierfeld G . Occupational history and genetic N-acetyltransferase polymorphism in urothelial cancer patients of Leverkusen, Germany. Scand J Work Environ Health. 1996; 22(5):332-8. DOI: 10.5271/sjweh.150. View

12.

Agundez J, Golka K, Martinez C, Selinski S, Blaszkewicz M, Garcia-Martin E . Unraveling ambiguous NAT2 genotyping data. Clin Chem. 2008; 54(8):1390-4. DOI: 10.1373/clinchem.2008.105569. View

13.

Jetter A, Kinzig M, Rodamer M, Tomalik-Scharte D, Sorgel F, Fuhr U . Phenotyping of N-acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be collected?. Eur J Clin Pharmacol. 2008; 65(4):411-7. DOI: 10.1007/s00228-008-0597-0. View

14.

Hein D . N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene. 2006; 25(11):1649-58. PMC: 1434721. DOI: 10.1038/sj.onc.1209374. View

15.

Hanioka N, Oka H, Nagaoka K, Ikushiro S, Narimatsu S . Effect of UDP-glucuronosyltransferase 2B15 polymorphism on bisphenol A glucuronidation. Arch Toxicol. 2011; 85(11):1373-81. DOI: 10.1007/s00204-011-0690-5. View

16.

Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein D . NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet. 2005; 366(9486):649-59. PMC: 1459966. DOI: 10.1016/S0140-6736(05)67137-1. View

17.

Lv X, Tang S, Xia Y, Zhang Y, Wu S, Yang Z . NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population. Ann Hepatol. 2012; 11(5):700-7. View

18.

Hein D, Doll M . Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes. Pharmacogenomics. 2011; 13(1):31-41. PMC: 3285565. DOI: 10.2217/pgs.11.122. View

19.

Tumer T, Sahin G, Arinc E . Association between polymorphisms of EPHX1 and XRCC1 genes and the risk of childhood acute lymphoblastic leukemia. Arch Toxicol. 2011; 86(3):431-9. DOI: 10.1007/s00204-011-0760-8. View

20.

Hein D . N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine. Expert Opin Drug Metab Toxicol. 2009; 5(4):353-66. PMC: 2762189. DOI: 10.1517/17425250902877698. View